Supriya Lifescience Limited

SUPRIYA

INE07RO01027

Pharmaceuticals

End-of-day quote NSE India S.E. Other stock markets 18:00:00 2024-06-04 EDT			5-day change	1st Jan Change
347.7 ^INR	+3.21%		-4.24%	+10.47%

05-28	Supriya Lifescience Limited Approves Executive Changes	CI
05-28	Supriya Lifescience Limited Recommends Final Dividend for the Fiscal 2024	CI

Supriya Lifescience Limited Resignation of Balasaheb Sawant as Whole Time Director

January 23, 2023 at 08:01 am

Supriya Lifescience Limited informed that Mr. Balasaheb Sawant, Whole Time Director and Key Managerial Personnel of the Company, has tendered his resignation with effect from January 23, 2023, due to the personal reason.

Latest news about Supriya Lifescience Limited

Supriya Lifescience Limited Approves Executive Changes	05-28	CI
Supriya Lifescience Limited Recommends Final Dividend for the Fiscal 2024	05-28	CI
Supriya Lifescience Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-28	CI
Supriya Lifescience Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-28	CI
Supriya Lifescience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-07	CI
Supriya Lifescience Limited Announces Approval of Capital Expenditure at Ambernath Site for CDMO Facility	02-07	CI
Supriya Lifescience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-07	CI
Supriya Lifescience Gets Brazil's Health Authority's GMP Certification for Site in India	01-05	MT
Supriya Lifescience Ltd Signs Agreement with Kalinga Institute of Technology for Further Development of Wound Healing Gel	11-06	CI
Supriya Lifescience Ties Up with Kalinga Institute for Oral Cancer Detection Kit	23-10-24	MT
Supriya Lifescience Ltd Collaborates with Kalinga Institute of Industrial Technology to Develop One of its Kind Oral Cancer Detection Kit Named Quickblue Oral Kit	23-10-23	CI
Supriya Lifescience Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-03	CI
Supriya Lifescience Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-03	CI
Supriya Lifescience Ltd. and Plasma Nutrition, Inc Announce Collaboration in Protein Technology	23-08-02	CI
Supriya Lifescience Limited Executes A Long-Term Supply and Sales Agreement with A Leading Company in Europe for the Supply of Active Pharmaceutical Ingredient	23-05-29	CI
Supriya Lifescience Limited Recommends Final Dividend for the Year Ended March 31, 2023	23-05-26	CI
Supriya Lifescience Names President for Business Development, Strategy and R&D	23-05-26	MT
Supriya Lifescience Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-26	CI
Supriya Lifescience Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-26	CI
Supriya Lifescience Limited Announces Resignation of Manoj Dorlikar as Whole Time Director	23-05-26	CI
Supriya Lifescience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Supriya Lifescience Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 30, 2022	23-02-14	CI
Supriya Lifescience Appoints CFO	23-01-23	MT
Supriya Lifescience Limited Resignation of Balasaheb Sawant as Whole Time Director	23-01-23	CI
Supriya Lifescience Limited Announces CFO Changes	23-01-23	CI

Chart Supriya Lifescience Limited

Duration

Period

More charts

Company Profile

Supriya Lifescience Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs). The Company is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals. The Company exports its products in the antihistamine, anesthetics and anti-asthma therapy categories to approximately 86 countries. The Company's product portfolio consists of approximately 38 niche API products that address remedies in therapeutic segments, such as antihistamine, analgesic, vitamin, anesthetics and anti-asthmatics, among others. The Company has manufacturing facilities located in Maharashtra. Its products include Chlorphenamine Maleate, Pheniramine Maleate, Brompheniramine Maleate, Dexchlorpheniramine Maleate, Mepyramine / Pyrilamine Maleate, Dexbrompheniramine Maleate, Cetirizine DiHCL, Diphenhydramine HCL, Bisoprolol Fumarate, Nicorandil, Mecobalamin, Hydroxocobalamin Sulphate, Hydroxocobalamin Acetate, and Hydroxocobalamin Hydrochloride, among others.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Supriya Lifescience Limited

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUPRIYA LIFESCIENCE LIMITED	+10.47%	325M
ELI LILLY AND COMPANY	+43.39%	750B
NOVO NORDISK A/S	+34.11%	606B
JOHNSON & JOHNSON	-6.61%	356B
MERCK & CO., INC.	+19.09%	326B
ABBVIE INC.	+6.96%	286B
ASTRAZENECA PLC	+18.08%	246B
ROCHE HOLDING AG	-3.44%	213B
NOVARTIS AG	+11.35%	213B
PFIZER, INC.	+2.01%	167B

Other Pharmaceuticals